Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study

Table 4 Association between the general cognitive factor and inflammatory markers in breast cancer survivors and in non-exposed participants stratified for mean body mass index

Inflammatory marker per SD increase	Breast cancer survivors		Non-exposed participants		P for interaction^†
Inflammatory marker per SD increase	Mean difference*	95% CI	Mean difference*	95% CI	P for interaction^†
BMI < 27.3 kg/m²
	n = 104		n = 749
Log GLR	−0.29	−0.49 to −0.10	−0.04	−0.10 to 0.02	0.480
Log PLR	−0.22	−0.42 to −0.02	0.01	−0.05 to 0.08	0.309
Log SII	−0.28	−0.48 to −0.09	−0.04	−0.10 to 0.02	0.564
BMI > 27.3 kg/m²
	n = 62		n = 595
Log GLR	−0.16	−0.41 to 0.09	0.01	−0.06 to 0.08	0.013
Log PLR	−0.16	−0.42 to 0.10	0.05	−0.02 to 0.12	<0.001
Log SII	−0.12	−0.38 to 0.14	0.02	−0.05 to 0.09	0.005

Abbreviations: BMI body mass index, CI confidence interval, GLR granulocyte-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, SD standard deviation, SII systemic immune-inflammation index
Model I is a linear regression of the general cognitive factor on each log-transformed inflammatory marker adjusted for age and education. Model II is as model I plus adjustment for smoking status, diabetes mellitus, history of stroke, history of myocardial infarction, and Center for Epidemiologic Studies Depression Scale (CES-D) sum-score.
*Mean difference in general cognitive factor per standard deviation increase in inflammatory marker
^†P value for interaction term between history of cancer/cancer treatment and inflammatory marker

ISSN: 1465-542X